Dana Miller
Nurse Practitioner · Kansas City, KSNPI 1073943064
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 50.3% of the total. Reporting peaked in 2021 at $5,642 and has fallen 68.0% since, to $1,806 in 2025. Among nurse practitioner clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $60.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$7K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$880
- AstraZeneca$683
- Akcea Therapeutics, Inc.$620
- Merck$588
- Abbott$586
- plus $3K from 21 others
What the payments were for
- Consulting fees$1,34010%
- Speaking & faculty fees$4,76536%
- Travel & lodging$3703%
- Food & beverage$6,87952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 29 | $6,719 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $880 |
| AstraZeneca | 23 | $683 |
| Akcea Therapeutics, Inc. | 1 | $620 |
| Merck | 29 | $588 |
| Abbott | 13 | $586 |
| Novartis | 24 | $579 |
| Impulse Dynamics (USA) Inc. | 9 | $449 |
| Pfizer | 22 | $410 |
| Boston Scientific | 5 | $300 |
| Endotronix, Inc. | 2 | $261 |
| Novo Nordisk | 7 | $257 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $212 |
| E.r. Squibb & Sons, L.L.C. | 7 | $152 |
| Boehringer Ingelheim | 5 | $120 |
| Amgen | 6 | $111 |
| Medtronic | 2 | $102 |
| Scpharmaceuticals Inc. | 5 | $94 |
| Edwards Lifesciences | 1 | $43 |
| Sanofi-aventis U.S. LLC | 1 | $39 |
| Bridgebio Pharma, Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Ancora Heart, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,354 in reported general payments places this provider in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 103 | $2,142,770 |
| JardianceEmpagliflozin | 122 | $163,748 |
| EliquisApixaban | 74 | $78,846 |
| EntrestoSacubitril/Valsartan | 64 | $73,302 |
| FarxigaDapagliflozin Propanediol | 59 | $53,784 |
| Bumetanide | 83 | $3,802 |
| Midodrine Hcl | 19 | $3,193 |
| Metoprolol Succinate | 158 | $2,150 |
| Potassium Chloride | 53 | $1,463 |
| Spironolactone | 162 | $1,233 |
| Carvedilol | 89 | $1,217 |
| Eplerenone | 11 | $1,033 |
| Torsemide | 33 | $996 |
| Furosemide | 88 | $508 |
| Bisoprolol Fumarate | 12 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $410 | $2,221,615177 claims |
| Boehringer IngelheimJardiance | $120 | $163,748122 claims |
| NovartisEntresto | $579 | $73,30264 claims |
| AstraZenecaFarxiga | $683 | $53,78459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Kansas City
- Jason OralloKansas City$10K
- Ashlee OrndorffKansas City$7K
- Paul WohletzKansas City$6K
- Emily OstranderKansas City$5K
- Gary GrafTopeka$726K
- Anna ShortRoeland Park$215K
- Shannon GreggTopeka$140K
- Morteza RabiiOverland Park$88K
- Constance JacobWichita$65K
- Michelle KirkHutchinson$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.